Moderna Study update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, good evening, and thank you for joining us today. This is a very exciting day for our cancer patients. It's an exciting day for cancer immunologists, and it's an exciting day for Moderna. Here's our forward-looking statement. Today, I'm going to start by giving just some brief contextual statements on intismeran. I'll then invite Dr. Georgina Long, who was the lead investigator for INTerpath-001 and gave a fantastic presentation today, to give a reprise of that presentation. I'll conclude with a few concluding statements, and then we're very fortunate to have two world experts in melanoma, Professor Ascierto, who was the senior author of INTerpath-001, and Professor Ribas, who is a melanoma expert and a world leader in cancer immunotherapy as well. Immune surveillance controls emerging cancer cells, and it does this by detecting neoantigens that form in cancer cells.
These neoantigens drain or are carried to regional lymph nodes. They're processed in antigen-presenting cells and then brought to the surface of the antigen-presenting cell and presented to T cells. T cells that recognize these neoantigens are activated. They circulate throughout the body looking for the cancer, and they eliminate the cancer. However, as we know, cancer can escape immune surveillance when either the cancer lacks sufficient neoantigens, the neoantigens aren't released or aren't transported to the lymph node, the antigen-presenting cells don't process them or present them on the surface, the T cell is insufficiently activated, or the T cells become exhausted. Checkpoints act on T cells. Anti-PD-1, PD-L1 reverse T cell exhaustion, and anti-CTLA-4 lowers the threshold for T cell activation. However, they act only on T cells and are limited by whatever available neoantigens are present in that lymph node.
Intismeran, as shown today by the phase III data, has an entirely different mechanism. It optimizes neoantigen presentation. How does it do this? First, we take the tumor out of the patient and use an algorithm to select the most promising neoantigens. We package those neoantigens into an mRNA lipid nanoparticle, and that's used to inject into the muscle of the patient. Now, we know from non-human primate studies and from rodent studies that when an mRNA LNP is injected into muscle, it drains into the regional lymph node, is taken up by antigen-presenting cells and dendritic cells. The RNA is produced into protein, and that protein, in the case of our neoantigen intismeran, can be presented on the surface. So there are three important points to take away about why we think intismeran is so potent.
First, high neoantigen expression in the cells where it's required, in the antigen-presenting cells, and in the dendritic cells. Number two, this is in an optimal environment. It's far away from the immunosuppressive microenvironment of the tumor. Number three, because CD4 and CD8 T cells are activated, dendritic cells are activated, and cytokines are released, there's a perfect milieu to create polyfunctional CD4 and CD8 T cells. And we have translational data to support some of these. Let me take you to ASCO 2026, just a few months ago, where we presented the phase II data. I'd first like to draw your attention to the initial phase II data that was presented a few years ago. Recall the hazard ratio at the primary analysis, which had the same follow-up as INTerpath-001 today. The hazard ratio was 0.561 at the primary analysis.
With longer follow-up, as we showed a few months ago, the hazard ratio improved to 0.51. Now, why did the hazard ratio improve? This can be seen looking at the arcs of the Kaplan-Meier curve. For the first 6 months, on the left-hand side, the Kaplan-Meier's are overlapping. As you heard today from Dr. Long, this is in part due to the weeks required to produce the intismeran and then weeks or a month for the immune system to be activated. At month 6, the curves separate, and we know they'll eventually remain separated. However, in the primary analysis, that first 6 months takes up about a quarter of the entire Kaplan-Meier curve. That hazard ratio 1 for the first 6 months takes up a quarter of that curve.
In the longer 5-year follow-up, that 6-month hazard ratio 1 is still there, but now we have follow-up up to 60 months, and therefore, that initial 6 months takes up but a fraction of the entire hazard ratio. This is why we pre-specified to conduct a piecewise analysis at 6 months, and you'll hear that from Dr. Long during her presentation. But it's very important, I think, to recall that the primary hazard ratio was essentially identical to what you'll hear today. 0.561 in this analysis, and we do believe the phase III data, for this reason, will continue to improve. intismeran, as I mentioned, activates T cells, and we should expect to see novel T cell clones in the peripheral blood. This is a figure. The Y-axis is the sum of novel T cells that we detect in the blood, and the X-axis is 4 different time points.
Baseline, post the pembrolizumab lead-in, and just prior to intismeran at cycle 5, so in the middle of the intismeran regimen, and then at a follow-up. This is the phase II intismeran plus pembro versus pembro. For the first portion, notice the 2 arms are overlapping because both groups of patients are receiving pembrolizumab, exactly what you would expect to see. However, once intismeran is administered, the combination curve continues to go up. More novel T cell clones are generated compared to the control arm. This leads to the question we asked, would higher levels of novel T cell clones be associated with clinical benefit? In theory, this should be most evident in the combination arm. That's exactly what we see. So the same Y-axis is the number of unique clones, X-axis is the same.
On the left-hand side is the combination arm, and on the right-hand side is the pembrolizumab arm. Now we've separated the patients into 2 groups. Those who, quote, "had benefit," i.e., never had a recurrence, and those who had, let's say, no benefit, those who had a recurrence. We did that for both arms. You'll notice for the combination arm, patients who had no recurrence, which is the top, their novel T cell clones continued to increase during treatment, whereas the ones who had recurrence plateaued. For the pembrolizumab arm, there's an initial increase and then there's a plateau. So this is evidence that there's an association mechanistically between the number of novel T cell clones and clinical benefit. Now, these are novel T cell clones, and we don't know if they are related to the intismeran drug product.
It is a little more complex to match T cells to neoantigens, but we were able to do it in 7 patients. This requires a lot more blood than is typically taken during the routine blood assessment. We consented 7 patients, and we matched their T cells to the 34 neoantigens they received in their cassette. What we found is, on average, one out of every three neoantigens in the 34 cassette is immunogenic. That is, it induces a T cell that is novel in the blood that reacts specifically to that neoantigen peptide. It ranges from about one to 18. Interestingly, it includes both CD4 and CD8 T cells. We then sought to further characterize the phenotype of these T cells.
We find, this is an example, it is a CD8 T cell that recognizes neoantigen 14 from patient three, and a CD4 T cell that recognizes neoantigen 27. When we phenotype it using flow cytometry, what we see is that both T cell clones are polyfunctional, they make different types of cytokines, and they also have markers of a cytotoxic phenotype, meaning that they are ready to go out and kill the cancer cell. Because we were able to clone out those T cells that recognize those neoantigens, we had the TCR sequences, and we could go back to whole blood, and we could follow the frequency or the prevalence of those T cells during treatment. It is the same timeframe on the bottom, screening, lead-in with pembrolizumab, in the middle of the intratumoral regimen, and then at the end.
What you will see in these three examples, that all T cell clones only appear after intratumoral, not during pembrolizumab, and most of them remain elevated for the entirety of the treatment. As a side note for those who are immunologists, one of the interesting features, which is known, is that there are usually multiple T cell clones that can recognize the same neoantigen peptide. At this point, I would like to invite up Dr. Georgina Long to give the presentation of INTerpath-001, and then I will return to give a few closing comments. Please come up this way so you do not fall. Okay. Thank you. And you press this one to advance Okay strangely.
Okay. Thank you. Thank you. It is a pleasure to present these data again to a smaller, more cozy audience. It is a true honor to be able to present results on something so transformational for cancer. This is a phase III randomized clinical trial of intismeran combined with pembrolizumab. We refer to intismeran as a type of INT therapy versus pembrolizumab alone for the adjuvant treatment of Stage 2B up to Stage 4 melanoma. I do not have my glasses, but I can see this slide. I am not that blind. I do present this on behalf of my co-investigators. There were 157 global sites and all of their teams. These are my disclosures. We know that there is a clinical benefit for the adjuvant treatment of melanoma patients with anti-PD-1 monotherapy alone. That is clear. Shown here are the two curves for Stage 3 resected melanoma and Stage 2 resected melanoma, Stage 2B.
The red curve is placebo. The blue curve is pembrolizumab alone. Yet, despite their significant clinical benefit and absolutely changing the field, we still have 44% and 33% of patients recurring or dying at 5 years. In the melanoma field, we see that there is a lot more work to do in terms of getting to zero deaths and to curing cancer. It is not that we have not been working at it. These are three landmark phase III clinical trials combining anti-PD-1 with three different checkpoints, CTLA-4, LAG-3, and anti-TIGIT, all negative. We have not had any improvement in the adjuvant setting over and above anti-PD-1. Sorry, go back again. What I presented today was really asking the oncology world, how did we get here to reflect on how we got here in 2026?
There really is over 100 years of work in immunology, cancer biology, and the technological innovation that has happened, particularly in the last 60 years. If you are looking at where we are today with intismeran, there are three really important scientific advances. First of all, the discovery that neoantigens exist back in the 1980s. These are unique mutations that are only found in an individual's tumor. They are not found in their normal cells, and they are not found in anyone else's cancer. That begs the question, if they are so unique, could they be seen as foreign to that patient's immune system?
Then the second big scientific advance is really built on next-generation sequencing, and that's the ability to rapidly sequence the tumor and also use the computational algorithms to identify and rank which neoantigens we think or we predict will give us the most robust anti-tumor response. The third is a platform that really is built for speed, and that's the fact that mRNA, you can include many, multiple antigens in a single strand of mRNA. There's demonstrated robust CD4 and CD8 tumor response or responses to these proteins. That's wrapped in a lipid nanoparticle, injected into the patient. Altogether, that is a very rapid, individualized manufacturing process giving us intismeran. Intismeran, as you heard before, encodes up to 34 neoantigens, and this is based on the patient's individual, what we call tumor mutanome, and their HLA type.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
11 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
